1. U.S. Department of Health and Human Services. Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Available at: http://www.fda.gov/cder/guidance/3625fnl.pdf. Accessed January 10, 2006.
2. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients With Impaired Hepatic Function. Available at: http://www.emea.eu.int. Accessed January 10, 2006.
3. Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P. Stereoselective biotransformation of the selective serotonin reuptake inhibitor RS-citalopram and its demethylated metabolites by monoamine oxidases in human liver.Biochem Pharmacol. 1998;56:15–23.
4. Von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.Drug Metab Dispos. 2001;29: 1102–1109.
5. Hyttel J, Arnt J, Sánchez C. The pharmacology of citalopram. RevContemp Pharmacother. 1995;6:271–285.